



Continue in the next page.



Continue in the next page.



◀ **Figure S1. Concentrations of the analytes in the discovery cohort, surgical controls and non-NSTI.** The boxplots depict the median and the first and third quartiles, whisker extends to the smallest and largest values or 1.5 times the inter-quartile range at most. NSTI: Necrotizing soft tissue infection, S. Control: Surgical controls, Non-NSTI: Suspected NSTI but no necrotic tissue found upon surgical exploration.




Figure S2. Significantly elevated concentration of Thrombomodulin in the NSTI discovery cohort as compared to both the surgical control and non-NSTI control cohorts. (A) Measured levels of thrombomodulin. (B) ROC curves of thrombomodulin and selected clinical markers. The legend shows the AUC (Area under the curve) of each curve. (C) NSTI patients were categorized in three groups based on NSTI signs: Early (severe pain, in need of opioids), intermediate (skin bullae or skin bruising) and late (skin purple/black discoloration, skin anesthesia, palpable gas (crepitus) or gas visualized on radiology) signs of NSTI. Statistical testing was performed using Kruskal-Wallis (KW) test followed by Dunn's post hoc test. The resulting p-value of the KW test was 7.62×10^{-15} and the significant differences between patients with early signs and the different groups are shown with stars (*= p-value < 0.05, and ***= p-value<0.005). The boxplots depict the median and the first and third quartiles, whisker extends to the smallest and largest values or 1.5 times the inter-quartile range at most. NSTI: Necrotizing soft tissue infection, S. controls: Surgical controls, Non-NSTI: Suspected NSTI but no necrotic tissue found upon surgical exploration, WBC: white blood cells, CRP: C-reactive protein.

Table S1. Results of the ROC analyses and the random forest model discriminating NSTI (discovery cohort) and non-NSTI. The ROC results are shown as the mean values of the iterations. Thresholds are given as pg/ml. The p-values of the random forest results were calculated using 100 permutations of the original dataset. (*Continues in the next page*)

| Analyte | Receiver operating characteristic | | | | | Random Forest | | | | | |
|------------------------|-----------------------------------|-------------|------------|------|------|---------------|-------------|------|-------------------------|-------|-------------|
| | AUC | [95% CI] | Threshold | Sn | Sp | Only proteins | | | with Clinical variables | | |
| | | | | | | MDA | p-val | MDG | p-val | MDA | p-val |
| CCL2/MCP-1 | 0.77 | [0.61-0.93] | 376.39 | 0.79 | 0.71 | 18.87 | 1.00 | 0.43 | 1.00 | 14.60 | 1.00 |
| CCL4/MIP-1 β | 0.77 | [0.62-0.93] | 727.39 | 0.78 | 0.72 | 26.45 | 1.00 | 0.34 | 1.00 | 23.16 | 1.00 |
| CCL5/RANTES | 0.68 | [0.5-0.86] | 3944.64 | 0.63 | 0.75 | 63.37 | 0.03 | 1.79 | 0.13 | 73.29 | 0.01 |
| CXCL8/IL-8 | 0.82 | [0.67-0.96] | 20.10 | 0.80 | 0.80 | 82.91 | 0.32 | 2.02 | 0.01 | 56.38 | 0.44 |
| CXCL10/IP-10 | 0.61 | [0.42-0.8] | 152.17 | 0.56 | 0.72 | 39.35 | 0.86 | 0.47 | 1.00 | 29.20 | 0.89 |
| IL-1 α | 0.79 | [0.64-0.94] | 40.81 | 0.76 | 0.73 | 44.35 | 0.99 | 0.69 | 0.81 | 20.37 | 1.00 |
| IL-1 β | 0.72 | [0.55-0.89] | 11.32 | 0.69 | 0.71 | 32.58 | 0.99 | 0.41 | 1.00 | 33.93 | 0.90 |
| IL-2 | 0.68 | [0.5-0.86] | 311.64 | 0.61 | 0.77 | 59.79 | 0.80 | 1.15 | 0.21 | 31.93 | 0.95 |
| IL-4 | 0.74 | [0.57-0.91] | 168.42 | 0.73 | 0.71 | 25.96 | 1.00 | 0.36 | 1.00 | 29.11 | 0.99 |
| IL-6 | 0.74 | [0.58-0.91] | 146.03 | 0.74 | 0.77 | 30.89 | 1.00 | 0.45 | 1.00 | 25.81 | 0.99 |
| IL-10 | 0.64 | [0.45-0.82] | 22.93 | 0.59 | 0.72 | 36.92 | 0.98 | 0.59 | 0.98 | 20.72 | 0.95 |
| IL-12p70 | 0.65 | [0.46-0.84] | 92.97 | 0.62 | 0.74 | 50.95 | 0.90 | 0.61 | 0.92 | 52.84 | 0.66 |
| IL-13 | 0.75 | [0.58-0.92] | 1012.96 | 0.72 | 0.79 | 47.89 | 0.88 | 0.65 | 0.87 | 34.21 | 0.90 |
| IL-17A | 0.81 | [0.67-0.96] | 9.83 | 0.74 | 0.82 | 61.77 | 0.71 | 1.68 | 0.07 | 57.75 | 0.46 |
| IL-18 | 0.73 | [0.56-0.9] | 346.26 | 0.66 | 0.77 | 55.42 | 0.36 | 0.97 | 0.63 | 20.87 | 0.73 |
| IL-22 | 0.76 | [0.6-0.92] | 83.65 | 0.74 | 0.75 | 65.21 | 0.84 | 0.87 | 0.46 | 26.68 | 1.00 |
| IL-36 β /IL-1F8 | 0.77 | [0.61-0.93] | 11.62 | 0.74 | 0.78 | 38.57 | 1.00 | 0.44 | 1.00 | 32.73 | 0.96 |
| E-Selectin | 0.71 | [0.54-0.88] | 67632.87 | 0.64 | 0.77 | 18.94 | 1.00 | 0.38 | 1.00 | 6.82 | 0.95 |
| ICAM-1 | 0.78 | [0.63-0.93] | 489976.27 | 0.74 | 0.74 | 93.12 | 0.06 | 1.28 | 0.27 | 31.26 | 0.48 |
| VCAM-1 | 0.77 | [0.61-0.92] | 2992116.00 | 0.76 | 0.69 | 26.32 | 0.76 | 0.76 | 0.84 | 12.91 | 0.93 |
| MMP-1 | 0.78 | [0.62-0.94] | 1294.94 | 0.79 | 0.74 | 105.17 | 0.02 | 2.11 | 0.04 | 78.36 | 0.03 |
| MMP-8 | 0.78 | [0.62-0.94] | 16814.91 | 0.78 | 0.74 | 40.65 | 0.90 | 0.97 | 0.54 | 26.08 | 0.92 |
| MMP-9 | 0.60 | [0.41-0.79] | 17904.72 | 0.60 | 0.67 | 26.01 | 0.87 | 0.41 | 1.00 | 19.39 | 0.91 |
| C5/C5a | 0.60 | [0.41-0.8] | 30650.78 | 0.58 | 0.74 | 28.39 | 0.15 | 0.76 | 0.85 | 32.52 | 0.06 |
| Collagen-IV α 1 | 0.73 | [0.57-0.9] | 1625.95 | 0.70 | 0.71 | 17.81 | 0.99 | 0.42 | 1.00 | 10.21 | 0.99 |
| Fas-Ligand | 0.55 | [0.35-0.74] | 26.12 | 0.63 | 0.57 | 46.23 | 0.55 | 0.70 | 0.89 | 44.66 | 0.32 |
| Galectin-3 | 0.70 | [0.52-0.88] | 2704.71 | 0.64 | 0.80 | 53.72 | 0.19 | 1.58 | 0.09 | 57.85 | 0.09 |
| G-CSF | 0.71 | [0.54-0.89] | 407.10 | 0.68 | 0.74 | 34.56 | 0.94 | 0.46 | 1.00 | 25.12 | 0.94 |
| I-alpha-1/COL1A1 | 0.65 | [0.46-0.84] | 7385.20 | 0.78 | 0.60 | 42.00 | 0.29 | 0.50 | 1.00 | 33.83 | 0.34 |

| | | | | | | | | | | | | | |
|----------------|------|-------------|----------|------|------|--------|-------------|------|-------------|--------|-------------|------|-------------|
| MPO | 0.67 | [0.48-0.85] | 30100.62 | 0.68 | 0.74 | 30.53 | 0.80 | 0.46 | 1.00 | 20.06 | 0.81 | 0.28 | 1.00 |
| Pentraxin-3 | 0.73 | [0.56-0.9] | 5726.70 | 0.69 | 0.75 | 12.05 | 1.00 | 0.47 | 1.00 | 9.11 | 1.00 | 0.30 | 0.97 |
| Resistin | 0.77 | [0.61-0.93] | 34604.01 | 0.73 | 0.79 | 38.53 | 0.71 | 0.70 | 0.93 | 15.00 | 0.79 | 0.22 | 1.00 |
| S100A8 | 0.72 | [0.54-0.9] | 547.20 | 0.74 | 0.74 | 21.63 | 1.00 | 1.14 | 0.16 | 24.16 | 0.99 | 0.85 | 0.06 |
| S100A9 | 0.70 | [0.51-0.9] | 1249.99 | 0.74 | 0.82 | 65.64 | 0.05 | 1.81 | 0.08 | 47.80 | 0.08 | 1.28 | 0.04 |
| Thrombomodulin | 0.95 | [0.89-1] | 7566.85 | 0.92 | 0.89 | 217.09 | 0.01 | 6.36 | 0.01 | 111.07 | 0.01 | 2.54 | 0.01 |
| TNF α | 0.84 | [0.72-0.97] | 18.50 | 0.79 | 0.77 | 62.90 | 0.87 | 1.69 | 0.03 | 54.80 | 0.68 | 0.80 | 0.06 |
| Age | NA | NA | NA | NA | NA | NA | NA | NA | NA | 28.14 | 0.15 | 0.59 | 0.51 |
| Sex | NA | NA | NA | NA | NA | NA | NA | NA | NA | -4.59 | 0.80 | 0.01 | 1.00 |
| SOFA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 29.43 | 0.59 | 0.64 | 0.06 |
| SS | NA | NA | NA | NA | NA | NA | NA | NA | NA | -0.51 | 0.87 | 0.03 | 0.48 |
| Type | NA | NA | NA | NA | NA | NA | NA | NA | NA | -4.19 | 0.98 | 0.02 | 0.94 |
| WBC | 0.58 | [0.38-0.78] | 16.64 | 0.58 | 0.71 | NA | NA | NA | NA | 2.05 | 0.96 | 0.17 | 1.00 |
| CRP | 0.59 | [0.4-0.79] | 271.16 | 0.60 | 0.66 | NA | NA | NA | NA | 56.92 | 0.02 | 0.86 | 0.12 |
| Creatinine | 0.71 | [0.53-0.89] | 105.29 | 0.67 | 0.77 | NA | NA | NA | NA | 17.31 | 0.50 | 0.24 | 0.99 |

AUC: Area under the curve, CI: Confidence interval, Sn: Sensitivity, Sp: Specificity, MDA: Mean decrease accuracy, MDG: Mean decrease gini; SOFA: Sequential organ failure assessment score, SS: Septic shock, WBC: white blood cells, CRP: C -reactive protein, Type: microbiological classification of NSTI.

Table S2. Results of the ROC analyses and random forest model discriminating type I and type II NSTI in the discovery cohort.

The ROC results are presented as the mean values of the iterations. Thresholds are given as pg/ml. The p-values of the random forest results were calculated using 100 permutations of the original dataset. (*Continues in the next page*)

| Analyte | Receiver operating characteristic | | | | | Random Forest | | | | | | | |
|------------------------|-----------------------------------|-------------|------------|------|------|---------------|-------------|-------|-------------------------|--------|-------------|-------|-------------|
| | | | | | | Only proteins | | | with Clinical variables | | | | |
| | AUC | [95% CI] | Threshold | Sn | Sp | MDA | p-val | MDG | p-val | MDA | p-val | MDG | p-val |
| CCL2/MCP-1 | 0.59 | [0.51-0.66] | 645.84 | 0.60 | 0.56 | 34.59 | 0.04 | 2.70 | 0.99 | 22.74 | 0.14 | 2.25 | 0.91 |
| CCL4/MIP-1 β | 0.59 | [0.51-0.66] | 807.17 | 0.57 | 0.59 | 58.42 | 0.02 | 2.66 | 1.00 | 42.21 | 0.03 | 2.18 | 0.90 |
| CCL5/RANTES | 0.53 | [0.45-0.6] | 7411.44 | 0.50 | 0.58 | 3.88 | 0.26 | 2.37 | 1.00 | 1.34 | 0.36 | 1.96 | 1.00 |
| CXCL-8/IL-8 | 0.51 | [0.43-0.59] | 52.10 | 0.64 | 0.46 | 54.46 | 0.04 | 2.75 | 1.00 | 52.60 | 0.02 | 2.43 | 0.86 |
| CXCL10/IP-10 | 0.83 | [0.78-0.89] | 216.01 | 0.79 | 0.79 | 369.04 | 0.01 | 19.89 | 0.01 | 321.92 | 0.01 | 15.88 | 0.01 |
| IL-1 α | 0.65 | [0.58-0.72] | 50.20 | 0.70 | 0.56 | 52.35 | 0.03 | 2.25 | 1.00 | 47.70 | 0.02 | 1.94 | 1.00 |
| IL-1 β | 0.52 | [0.44-0.6] | 13.79 | 0.46 | 0.62 | 36.04 | 0.02 | 2.34 | 1.00 | 26.95 | 0.03 | 2.02 | 0.99 |
| IL-2 | 0.74 | [0.67-0.8] | 523.28 | 0.75 | 0.67 | 132.37 | 0.01 | 6.88 | 0.01 | 115.87 | 0.01 | 5.61 | 0.01 |
| IL-4 | 0.65 | [0.58-0.72] | 200.11 | 0.67 | 0.60 | 57.07 | 0.01 | 2.54 | 0.99 | 44.48 | 0.03 | 2.03 | 0.94 |
| IL-6 | 0.61 | [0.53-0.68] | 451.85 | 0.62 | 0.56 | 31.78 | 0.04 | 1.95 | 1.00 | 23.63 | 0.10 | 1.69 | 1.00 |
| IL-10 | 0.70 | [0.63-0.77] | 38.56 | 0.73 | 0.66 | 138.72 | 0.01 | 5.96 | 0.02 | 117.95 | 0.01 | 4.63 | 0.01 |
| IL-12p70 | 0.66 | [0.58-0.73] | 165.10 | 0.75 | 0.53 | 79.49 | 0.01 | 3.19 | 0.50 | 75.22 | 0.01 | 2.72 | 0.25 |
| IL-13 | 0.61 | [0.54-0.69] | 1280.83 | 0.62 | 0.57 | 30.65 | 0.08 | 1.97 | 1.00 | 21.10 | 0.06 | 1.58 | 1.00 |
| IL-17A | 0.67 | [0.6-0.74] | 19.83 | 0.67 | 0.61 | 106.05 | 0.01 | 3.71 | 0.27 | 89.56 | 0.01 | 3.08 | 0.18 |
| IL-18 | 0.60 | [0.53-0.68] | 471.26 | 0.63 | 0.60 | 8.50 | 0.17 | 2.05 | 1.00 | -2.71 | 0.48 | 1.57 | 1.00 |
| IL-22 | 0.73 | [0.66-0.8] | 104.19 | 0.77 | 0.63 | 152.12 | 0.01 | 6.81 | 0.01 | 135.53 | 0.01 | 5.46 | 0.01 |
| IL-36 β /IL-1F8 | 0.65 | [0.58-0.73] | 14.89 | 0.61 | 0.66 | 71.62 | 0.01 | 2.41 | 1.00 | 53.63 | 0.01 | 1.86 | 1.00 |
| E-Selectin | 0.67 | [0.6-0.74] | 109952.76 | 0.68 | 0.61 | 74.10 | 0.01 | 3.42 | 0.65 | 58.02 | 0.01 | 2.78 | 0.61 |
| ICAM-1 | 0.62 | [0.55-0.7] | 595130.42 | 0.67 | 0.59 | 40.08 | 0.03 | 2.33 | 1.00 | 52.16 | 0.03 | 2.27 | 0.99 |
| VCAM-1 | 0.65 | [0.57-0.72] | 3490787.00 | 0.57 | 0.67 | 50.67 | 0.02 | 3.68 | 0.67 | 59.37 | 0.02 | 3.24 | 0.39 |
| MMP-1 | 0.56 | [0.48-0.64] | 1679.64 | 0.63 | 0.55 | 43.03 | 0.02 | 3.23 | 0.97 | 30.76 | 0.06 | 2.09 | 1.00 |
| MMP-8 | 0.52 | [0.44-0.59] | 27284.41 | 0.60 | 0.47 | 40.52 | 0.07 | 3.16 | 0.88 | 34.77 | 0.05 | 2.59 | 0.68 |
| MMP-9 | 0.71 | [0.64-0.78] | 8858.61 | 0.77 | 0.61 | 139.42 | 0.01 | 5.92 | 0.01 | 112.09 | 0.01 | 4.17 | 0.02 |
| C5/C5a | 0.51 | [0.43-0.59] | 20808.04 | 0.47 | 0.61 | 29.15 | 0.08 | 2.69 | 1.00 | 30.95 | 0.08 | 2.14 | 1.00 |
| Collagen-IV α 1 | 0.62 | [0.54-0.69] | 2011.76 | 0.64 | 0.61 | 13.23 | 0.26 | 2.83 | 0.98 | -1.30 | 0.45 | 2.19 | 1.00 |
| Fas-Ligand | 0.75 | [0.69-0.82] | 26.15 | 0.76 | 0.68 | 173.75 | 0.01 | 8.16 | 0.01 | 160.03 | 0.01 | 6.78 | 0.01 |
| Galectin-3 | 0.52 | [0.44-0.6] | 3538.70 | 0.45 | 0.65 | 17.74 | 0.18 | 2.37 | 1.00 | 21.67 | 0.10 | 2.06 | 1.00 |

| | | | | | | | | | | | | | |
|------------------|------|-------------|----------|------|------|-------|-------------|------|------|--------|-------------|------|------|
| G-CSF | 0.68 | [0.61-0.75] | 987.78 | 0.70 | 0.60 | 79.39 | 0.02 | 2.98 | 0.93 | 72.78 | 0.01 | 2.58 | 0.60 |
| I-alpha-1/COL1A1 | 0.66 | [0.59-0.73] | 7214.79 | 0.58 | 0.71 | 16.78 | 0.13 | 3.01 | 1.00 | 21.27 | 0.10 | 2.55 | 0.93 |
| MPO | 0.52 | [0.44-0.6] | 37339.36 | 0.56 | 0.51 | 39.43 | 0.04 | 2.63 | 1.00 | 20.85 | 0.06 | 1.83 | 1.00 |
| Pentraxin-3 | 0.61 | [0.53-0.68] | 9159.10 | 0.59 | 0.62 | 42.35 | 0.06 | 2.56 | 1.00 | 45.98 | 0.02 | 2.34 | 0.95 |
| Resistin | 0.54 | [0.46-0.61] | 54190.86 | 0.59 | 0.51 | 12.62 | 0.17 | 2.50 | 1.00 | 9.84 | 0.17 | 1.99 | 1.00 |
| S100A8 | 0.63 | [0.56-0.71] | 732.57 | 0.63 | 0.61 | 50.82 | 0.03 | 2.15 | 1.00 | 44.01 | 0.04 | 1.80 | 1.00 |
| S100A9 | 0.59 | [0.52-0.67] | 3596.50 | 0.52 | 0.67 | 54.82 | 0.02 | 3.20 | 0.94 | 34.85 | 0.06 | 2.18 | 1.00 |
| Thrombomodulin | 0.52 | [0.44-0.6] | 11441.51 | 0.50 | 0.56 | -9.44 | 0.64 | 1.89 | 1.00 | -18.07 | 0.80 | 1.44 | 1.00 |
| TNF α | 0.63 | [0.56-0.71] | 26.75 | 0.66 | 0.60 | 44.68 | 0.04 | 2.11 | 1.00 | 32.18 | 0.07 | 1.67 | 1.00 |
| Age | NA | NA | NA | NA | NA | NA | NA | NA | NA | -0.42 | 0.42 | 1.27 | 1.00 |
| Sex | NA | NA | NA | NA | NA | NA | NA | NA | NA | -3.10 | 0.47 | 0.18 | 0.99 |
| SOFA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2.87 | 0.29 | 1.12 | 1.00 |
| SS | NA | NA | NA | NA | NA | NA | NA | NA | NA | 1.33 | 0.26 | 0.14 | 0.98 |
| WBC | 0.59 | [0.51-0.67] | 14.08 | 0.50 | 0.67 | NA | NA | NA | NA | 33.00 | 0.08 | 1.97 | 1.00 |
| CRP | 0.64 | [0.57-0.72] | 290.74 | 0.61 | 0.61 | NA | NA | NA | NA | 58.37 | 0.01 | 3.07 | 0.40 |
| Creatinine | 0.59 | [0.51-0.67] | 134.04 | 0.56 | 0.63 | NA | NA | NA | NA | 3.52 | 0.38 | 1.56 | 1.00 |

AUC: Area under the curve, CI: Confidence interval, Sn: Sensitivity, Sp: Specificity, MDA: Mean decrease accuracy, MDG: Mean decrease gini; SOFA: Sequential organ failure assessment score, SS: Septic shock, WBC: white blood cells, CRP: C -reactive protein.




Figure S3. None of the measured analytes displayed significant differences for prediction of mortality or amputation in the discovery cohort. (A and C) The median protein levels in each group are depicted in the heatmap. The measured proteins are divided by categories: I-Chemokines, II-Interleukins, III-Soluble adhesion molecules, IV- Matrix metalloproteases, and V-Others. Significant differences between the measured concentrations were tested using Mann-Whitney U test (MW). **(B and D)** Random forest results shown as the mean decrease Gini for each variable. SOFA: Sequential organ failure assessment score, SS: Septic shock, Amp,: amputation, Type: microbiological classification of NSTI.

Table S3. Results from the ROC analyses discriminating septic shock and non-septic shock presence in all cases, type I, and type II NSTI in the discovery cohort. The results are shown as the mean values of the iterations. Thresholds are given as pg/ml. (*Continues in the next page*)

| Analyte | All | | | | | Type I | | | | | Type II | | | | |
|------------------------|------|-------------|-----------|------|------|--------|-------------|-----------|------|------|---------|-------------|-----------|------|------|
| | AUC | [95% CI] | Threshold | Sn | Sp | AUC | [95% CI] | Threshold | Sn | Sp | AUC | [95% CI] | Threshold | Sn | Sp |
| CCL2/MCP-1 | 0.75 | [0.68-0.82] | 620.8 | 0.69 | 0.76 | 0.69 | [0.58-0.8] | 557.19 | 0.64 | 0.71 | 0.79 | [0.7-0.88] | 625.11 | 0.77 | 0.78 |
| CCL4/MIP-1 β | 0.72 | [0.65-0.79] | 793.25 | 0.75 | 0.68 | 0.66 | [0.55-0.77] | 793.06 | 0.67 | 0.72 | 0.78 | [0.68-0.87] | 827.33 | 0.71 | 0.74 |
| CCL5/RANTES | 0.53 | [0.46-0.61] | 7656.11 | 0.58 | 0.5 | 0.51 | [0.4-0.63] | 7155.43 | 0.56 | 0.51 | 0.56 | [0.44-0.67] | 6179.53 | 0.55 | 0.6 |
| CXCL8/IL-8 | 0.75 | [0.69-0.82] | 38.95 | 0.72 | 0.71 | 0.76 | [0.67-0.86] | 47.59 | 0.66 | 0.76 | 0.75 | [0.65-0.85] | 36.18 | 0.74 | 0.74 |
| CXCL10/IP-10 | 0.67 | [0.6-0.74] | 324.19 | 0.59 | 0.67 | 0.51 | [0.39-0.62] | 103.24 | 0.49 | 0.62 | 0.7 | [0.6-0.8] | 1297.83 | 0.64 | 0.67 |
| IL-1 α | 0.75 | [0.69-0.82] | 49.05 | 0.67 | 0.78 | 0.72 | [0.61-0.82] | 46.28 | 0.63 | 0.76 | 0.77 | [0.68-0.86] | 51.51 | 0.73 | 0.77 |
| IL-1 β | 0.69 | [0.62-0.76] | 15.94 | 0.63 | 0.68 | 0.67 | [0.56-0.77] | 18.19 | 0.57 | 0.74 | 0.72 | [0.62-0.82] | 15.16 | 0.69 | 0.7 |
| IL-2 | 0.72 | [0.65-0.79] | 498.43 | 0.66 | 0.69 | 0.66 | [0.55-0.77] | 371.54 | 0.61 | 0.7 | 0.75 | [0.65-0.84] | 663.96 | 0.73 | 0.66 |
| IL-4 | 0.76 | [0.69-0.82] | 201.45 | 0.69 | 0.77 | 0.69 | [0.58-0.8] | 178.91 | 0.68 | 0.68 | 0.79 | [0.7-0.89] | 206.75 | 0.79 | 0.76 |
| IL-6 | 0.78 | [0.71-0.84] | 419.48 | 0.71 | 0.78 | 0.74 | [0.64-0.84] | 402.75 | 0.66 | 0.81 | 0.79 | [0.71-0.88] | 608.89 | 0.72 | 0.79 |
| IL-10 | 0.75 | [0.68-0.81] | 32.1 | 0.71 | 0.7 | 0.7 | [0.6-0.8] | 22.01 | 0.6 | 0.76 | 0.77 | [0.68-0.86] | 60.92 | 0.67 | 0.78 |
| IL-12p70 | 0.72 | [0.65-0.79] | 154.45 | 0.65 | 0.8 | 0.68 | [0.57-0.79] | 138.16 | 0.6 | 0.77 | 0.74 | [0.64-0.84] | 155.7 | 0.73 | 0.75 |
| IL-13 | 0.72 | [0.65-0.79] | 1276.59 | 0.67 | 0.71 | 0.7 | [0.59-0.8] | 1274.32 | 0.61 | 0.77 | 0.72 | [0.61-0.82] | 1306.58 | 0.68 | 0.68 |
| IL-17A | 0.69 | [0.62-0.76] | 19.92 | 0.62 | 0.69 | 0.64 | [0.53-0.75] | 13.14 | 0.73 | 0.61 | 0.72 | [0.62-0.83] | 23.6 | 0.69 | 0.73 |
| IL-18 | 0.63 | [0.55-0.7] | 458.2 | 0.59 | 0.59 | 0.6 | [0.48-0.71] | 457.81 | 0.51 | 0.69 | 0.61 | [0.5-0.72] | 455.79 | 0.69 | 0.51 |
| IL-22 | 0.72 | [0.66-0.79] | 98.66 | 0.7 | 0.72 | 0.67 | [0.56-0.78] | 94.12 | 0.59 | 0.75 | 0.74 | [0.64-0.84] | 109.44 | 0.73 | 0.69 |
| IL-36 β /IL-1F8 | 0.74 | [0.68-0.81] | 15.91 | 0.64 | 0.8 | 0.67 | [0.56-0.78] | 13.74 | 0.66 | 0.65 | 0.8 | [0.71-0.89] | 16.25 | 0.74 | 0.8 |
| E-Selectin | 0.64 | [0.56-0.71] | 106330.13 | 0.61 | 0.64 | 0.58 | [0.47-0.69] | 82682.14 | 0.58 | 0.58 | 0.65 | [0.54-0.76] | 127423.41 | 0.66 | 0.66 |
| ICAM-1 | 0.63 | [0.56-0.71] | 590697.9 | 0.6 | 0.66 | 0.59 | [0.48-0.71] | 545439.14 | 0.6 | 0.65 | 0.66 | [0.55-0.76] | 663488.8 | 0.58 | 0.71 |
| VCAM-1 | 0.61 | [0.54-0.69] | 3820864 | 0.58 | 0.61 | 0.49 | [0.37-0.6] | 2786263.5 | 0.58 | 0.51 | 0.65 | [0.54-0.76] | 4147485 | 0.64 | 0.65 |
| MMP-1 | 0.61 | [0.54-0.69] | 1887.25 | 0.53 | 0.64 | 0.63 | [0.51-0.74] | 2132.29 | 0.54 | 0.66 | 0.63 | [0.52-0.74] | 1545.95 | 0.62 | 0.62 |
| MMP-8 | 0.71 | [0.64-0.78] | 26460.02 | 0.72 | 0.65 | 0.72 | [0.61-0.82] | 32722.57 | 0.66 | 0.73 | 0.71 | [0.61-0.82] | 23445.25 | 0.73 | 0.69 |
| MMP-9 | 0.7 | [0.63-0.77] | 12544.29 | 0.69 | 0.67 | 0.64 | [0.54-0.75] | 17731.22 | 0.64 | 0.64 | 0.72 | [0.62-0.82] | 12229.85 | 0.82 | 0.6 |
| C5/C5a | 0.52 | [0.44-0.6] | 19591.17 | 0.51 | 0.56 | 0.51 | [0.39-0.62] | 22388.13 | 0.6 | 0.5 | 0.54 | [0.43-0.66] | 19283.92 | 0.51 | 0.63 |
| Collagen-IV α 1 | 0.75 | [0.68-0.81] | 1933.49 | 0.71 | 0.71 | 0.72 | [0.61-0.82] | 1851.14 | 0.64 | 0.75 | 0.76 | [0.66-0.85] | 2078.03 | 0.76 | 0.67 |
| Fas-Ligand | 0.66 | [0.58-0.73] | 26.45 | 0.6 | 0.65 | 0.52 | [0.41-0.64] | 20.43 | 0.57 | 0.58 | 0.74 | [0.64-0.84] | 31.58 | 0.72 | 0.66 |
| Galectin-3 | 0.64 | [0.57-0.72] | 3283.99 | 0.6 | 0.64 | 0.69 | [0.59-0.8] | 3625.1 | 0.59 | 0.75 | 0.61 | [0.5-0.72] | 3230.36 | 0.61 | 0.63 |
| G-CSF | 0.79 | [0.73-0.85] | 673.45 | 0.76 | 0.76 | 0.77 | [0.67-0.86] | 501.72 | 0.7 | 0.8 | 0.81 | [0.73-0.9] | 1487.47 | 0.75 | 0.84 |
| I-alpha-1/COL1A1 | 0.68 | [0.6-0.75] | 7805.59 | 0.66 | 0.63 | 0.64 | [0.53-0.75] | 7428.67 | 0.56 | 0.72 | 0.67 | [0.56-0.78] | 8715.61 | 0.66 | 0.61 |
| MPO | 0.68 | [0.61-0.75] | 40200.88 | 0.58 | 0.74 | 0.63 | [0.52-0.74] | 43515.31 | 0.53 | 0.76 | 0.73 | [0.63-0.83] | 36569.84 | 0.7 | 0.72 |
| Pentraxin-3 | 0.74 | [0.68-0.81] | 7975.61 | 0.76 | 0.68 | 0.69 | [0.58-0.79] | 7317.16 | 0.68 | 0.68 | 0.77 | [0.68-0.87] | 9456.21 | 0.81 | 0.71 |
| Resistin | 0.63 | [0.55-0.7] | 50956.18 | 0.65 | 0.61 | 0.62 | [0.5-0.73] | 52193.54 | 0.63 | 0.66 | 0.63 | [0.52-0.74] | 49776.07 | 0.69 | 0.59 |
| S100A8 | 0.78 | [0.71-0.84] | 819.42 | 0.66 | 0.83 | 0.75 | [0.65-0.84] | 661.36 | 0.69 | 0.74 | 0.79 | [0.7-0.89] | 872.17 | 0.74 | 0.84 |

| | | | | | | | | | | | | | | | |
|----------------|------|-------------|----------|------|------|------|-------------|----------|------|------|------|-------------|---------|------|------|
| S100A9 | 0.55 | [0.48-0.63] | 3343.11 | 0.5 | 0.62 | 0.55 | [0.44-0.67] | 4018.29 | 0.54 | 0.6 | 0.58 | [0.47-0.69] | 2716.59 | 0.52 | 0.64 |
| Thrombomodulin | 0.62 | [0.54-0.69] | 12989.07 | 0.52 | 0.71 | 0.54 | [0.43-0.66] | 13253.96 | 0.45 | 0.7 | 0.68 | [0.58-0.79] | 12907.4 | 0.57 | 0.78 |
| TNF α | 0.72 | [0.65-0.79] | 26.3 | 0.67 | 0.71 | 0.64 | [0.53-0.75] | 25.64 | 0.56 | 0.77 | 0.77 | [0.68-0.86] | 30.2 | 0.71 | 0.74 |
| WBC | 0.60 | [0.52-0.68] | 14.72 | 0.55 | 0.66 | 0.61 | [0.5-0.73] | 15.50 | 0.55 | 0.69 | 0.58 | [0.47-0.7] | 14.02 | 0.58 | 0.62 |
| CRP | 0.51 | [0.43-0.59] | 322.79 | 0.46 | 0.64 | 0.57 | [0.45-0.68] | 383.58 | 0.47 | 0.77 | 0.52 | [0.4-0.64] | 241.02 | 0.49 | 0.64 |
| Creatinine | 0.63 | [0.56-0.71] | 131.10 | 0.61 | 0.65 | 0.55 | [0.43-0.66] | 115.03 | 0.55 | 0.60 | 0.70 | [0.59-0.81] | 140.79 | 0.69 | 0.68 |

Type I: Polymicrobial culture, Type II: monomicrobial culture, AUC: Area under the curve, CI: Confidence interval, Sn: Sensitivity, Sp: Specificity, WBC: White blood cells, CRP: C-reactive protein.

| | | | | | | | | | | | | | | | | | | | | | | | | |
|----------------|-----|-------------|-----|-------------|-----|-------------|-----|-------------|-----|-------------|-----|-------------|----|-------------|-----|-------------|-----|-------------|-----|-------------|-----|-------------|-----|-------------|
| S100A8 | 160 | 0.01 | 7.7 | 0.01 | 162 | 0.01 | 7.2 | 0.01 | 115 | 0.01 | 3.2 | 0.01 | 92 | 0.01 | 2.4 | 0.02 | 108 | 0.01 | 3.9 | 0.01 | 123 | 0.01 | 3.7 | 0.01 |
| S100A9 | 19 | 0.13 | 2.3 | 1.00 | 14 | 0.24 | 1.8 | 1.00 | 13 | 0.15 | 1.0 | 1.00 | 6 | 0.29 | 0.8 | 1.00 | 19 | 0.12 | 1.1 | 1.00 | 15 | 0.13 | 0.8 | 1.00 |
| Thrombomodulin | 53 | 0.02 | 3.1 | 1.00 | 29 | 0.02 | 2.5 | 0.82 | -2 | 0.48 | 1.3 | 0.94 | -1 | 0.33 | 1.1 | 0.87 | 44 | 0.03 | 2.0 | 0.36 | 31 | 0.06 | 1.3 | 0.67 |
| TNF α | 72 | 0.02 | 3.5 | 0.50 | 62 | 0.02 | 3.0 | 0.18 | 4 | 0.21 | 1.2 | 0.72 | 10 | 0.13 | 1.0 | 0.72 | 62 | 0.04 | 2.0 | 0.17 | 66 | 0.01 | 2.0 | 0.04 |
| Age | NA | NA | NA | NA | -1 | 0.37 | 1.7 | 1.00 | NA | NA | NA | NA | -4 | 0.50 | 0.9 | 0.95 | NA | NA | NA | NA | 25 | 0.08 | 1.0 | 0.96 |
| Sex | NA | NA | NA | NA | 22 | 0.03 | 0.4 | 0.13 | NA | NA | NA | NA | 41 | 0.01 | 0.6 | 0.01 | NA | NA | NA | NA | 0 | 0.26 | 0.1 | 0.96 |
| SOFA | NA | NA | NA | NA | 165 | 0.01 | 4.2 | 0.01 | NA | NA | NA | NA | 75 | 0.01 | 1.5 | 0.04 | NA | NA | NA | NA | 117 | 0.01 | 2.0 | 0.02 |
| WBC | NA | NA | NA | NA | 15 | 0.23 | 1.9 | 1.00 | NA | NA | NA | NA | -4 | 0.36 | 1.0 | 0.94 | NA | NA | NA | NA | 10 | 0.26 | 0.8 | 1.00 |
| CRP | NA | NA | NA | NA | 24 | 0.08 | 1.9 | 1.00 | NA | NA | NA | NA | 11 | 0.19 | 1.0 | 0.92 | NA | NA | NA | NA | 22 | 0.13 | 1.0 | 1.00 |
| Creatinine | NA | NA | NA | NA | 23 | 0.14 | 2.0 | 1.00 | NA | NA | NA | NA | 14 | 0.16 | 1.1 | 0.81 | NA | NA | NA | NA | 21 | 0.09 | 0.9 | 1.00 |

AUC: Area under the curve, CI: Confidence interval, Sn: Sensitivity, Sp: Specificity, MDA: Mean decrease accuracy, MDG: Mean decrease gini, SOFA: Sequential organ failure assessment score, SS: Septic shock, WBC: White blood cells, CRP: C-reactive protein.

Table S5. Clinical characteristics of the validation patient cohort and the additional sepsis cohort. The data are shown as mean values and standard deviations, or percentages.

| | NSTI | | | | p-value ^C | |
|----------------------------------|--------------------|--------------------|--------------------|------------------|----------------------|----------------------|
| | All (60) | Type I (39) | Type II (21) | Sepsis (24) | NSTI vs Sepsis | Type I vs Type II |
| Age (years) | 58 ± 14 | 58 ± 11 | 57 ± 18 | 69 ± 11 | 0.001 | 0.803 |
| Sex (male) | 39 (65%) | 24 (62%) | 15 (71%) | 16 (67%) | >0.999 | 0.573 |
| Septic shock at baseline | 29 (48%) | 17 (44%) | 12 (57%) | 11 (46%) | >0.999 | 0.506 |
| Amputation ^A | 3 (14%) | 1 (17%) | 2 (13%) | NA | NA | >0.999 |
| 90-day mortality | 8 (13%) | 5 (13%) | 3 (14%) | 4 (17%) | 0.735 | >0.999 |
| Comorbidities | 40 (67%) | 26 (67%) | 14 (67%) | NA | NA | >0.999 |
| Diabetes (Type I or II) | 13 (48%) | 11 (61%) | 2 (22%) | NA | NA | 0.114 |
| Cardiovascular disease | 27 (45%) | 18 (46%) | 9 (43%) | NA | NA | >0.999 |
| Surgery Before NSTI ^B | 16 (27%) | 14 (36%) | 2 (10%) | NA | NA | 0.034 |
| SAPS II | 44 ± 15 (3% NA) | 42 ± 13 (3% NA) | 49 ± 17 (5% NA) | NA | NA | 0.090 |
| SOFA at admission | 8 ± 3 (2% NA) | 7 ± 3 (0% NA) | 8 ± 4 (5% NA) | 4 ± 2 (0% NA) | <0.0001 | 0.425 |
| Type I | 39 (65%) | NA | NA | NA | NA | NA |
| Microbiological findings | | | | | | |
| GAS | 8 (13%) | 1 (3%) | 7 (33%) | 2 (8%) | 0.717 | 0.002 |
| Other Strep | 3 (5%) | 2 (5%) | 1 (5%) | 0 | 0.554 | >0.999 |
| <i>S. aureus</i> | 7 (12%) | 2 (5%) | 5 (24%) | 2 (8%) | >0.999 | 0.045 |
| <i>Clostridium sp.</i> | 1 (2%) | 1 (3%) | 0 (0%) | 0 | >0.999 | >0.999 |
| Others | 41 (68%) | 33 (85%) | 8 (38%) | 20 (83%) | 0.188 | <0.001 |

NSTI: Necrotizing soft tissue infection, type I: Polymicrobial culture, type II: monomicrobial etiology, NA: not applicable, SAPS II: Simplified acute physiology score II, SOFA: Sequential organ failure assessment score, GAS: Group A *Streptococcus*, Strep: *Streptococcus sp.*

^A Includes only infections in extremities (N=22; Type I=6)

^B Within 4 weeks before admission for NSTI

^C Significant differences between cohorts were determined by Mann-Whitney U test or Fisher's exact test.

Table S6. Statistical comparison of the characteristics of discovery cohort compared to the validation cohort.

| | p-value ^C | | |
|----------------------------------|---------------------------|--------|---------|
| | Discovery vs verification | | |
| | All | Type I | Type II |
| Age (years) | 0.445 | 0.576 | 0.546 |
| Sex (male) | 0.192 | 0.852 | 0.103 |
| Septic shock at baseline | 0.565 | 0.853 | >0.999 |
| Amputation ^A | 0.435 | >0.999 | >0.999 |
| 90-day mortality | 0.353 | 0.252 | >0.999 |
| Comorbidities | 0.434 | 0.211 | >0.999 |
| Diabetes (Type I or II) | 0.866 | 0.437 | >0.999 |
| Cardiovascular disease | 0.560 | 0.581 | 0.813 |
| Surgery Before NSTI ^B | 0.035 | 0.142 | 0.667 |
| SAPS II | 0.849 | 0.465 | 0.366 |
| SOFA at admission | 0.141 | 0.534 | 0.412 |
| Type I | 0.014 | NA | NA |
| Microbiological findings | | | |
| GAS | 0.0001 | 0.294 | 0.007 |
| Other Strep | 0.035 | 0.067 | 0.314 |
| <i>S. aureus</i> | 0.278 | 0.731 | 0.012 |
| <i>Clostridium sp.</i> | 0.475 | 0.681 | >0.999 |
| Others | <0.0001 | 0.006 | 0.003 |

NSTI: Necrotizing soft tissue infection, Type I: Polymicrobial culture, type II: monomicrobial etiology, NA: not applicable, SAPS II: Simplified acute physiology score II, SOFA: Sequential organ failure assessment score, GAS: Group A *Streptococcus*, Strep: *Streptococcus sp.*

^A Includes only infections in extremities

^B Within 4 weeks before admission for NSTI

^C Significant differences between cohorts were determined by Mann-Whitney U test or Fisher's exact test.

Table S7. Results of the ROC analyses applied in the validation cohort. Thresholds are given in pg/ml.

| | Comparison | Analyte | AUC | [95% CI] | Threshold | Sensitivity | Specificity |
|---------------|-------------------|----------------|------|-------------|-----------|-------------|-------------|
| NSTI | Sepsis vs NSTI | Thrombomodulin | 0.77 | [0.67-0.88] | 3972.01 | 0.75 | 0.75 |
| | | WBC | 0.75 | [0.63-0.87] | 13.30 | 0.76 | 0.79 |
| | | CRP | 0.75 | [0.63-0.87] | 153 | 0.83 | 0.67 |
| | | Creatinine | 0.52 | [0.39-0.66] | 114.50 | 0.61 | 0.58 |
| Type | NSTI cohort | CXCL-10 | 0.78 | [0.65-0.91] | 36.43 | 0.71 | 0.74 |
| | | MMP-9 | 0.66 | [0.51-0.81] | 34902.50 | 0.71 | 0.54 |
| | | IL-10 | 0.63 | [0.47-0.79] | 43.5 | 0.52 | 0.74 |
| | | Fas-Ligand | 0.55 | [0.39-0.72] | 1.88 | 0.79 | 0.42 |
| | Type I vs Type II | IL-2 | 0.64 | [0.49-0.78] | 6.02 | 0.71 | 0.53 |
| | | WBC | 0.57 | [0.4-0.74] | 14.30 | 0.48 | 0.79 |
| | | CRP | 0.50 | [0.34-0.66] | 242.5 | 0.52 | 0.61 |
| | | Creatinine | 0.61 | [0.44-0.77] | 106.00 | 0.62 | 0.63 |
| Septic Shock | NSTI cohort | CXCL-10 | 0.99 | [0.97-1] | 642.77 | 1 | 0.92 |
| | | MMP-9 | 0.60 | [0.33-0.87] | 16960.00 | 0.43 | 0.90 |
| | | IL-10 | 0.79 | [0.6-0.99] | 53.41 | 0.71 | 0.77 |
| | | Fas-Ligand | 0.74 | [0.56-0.92] | 2.61 | 0.86 | 0.58 |
| | Type I vs GAS | IL-2 | 0.82 | [0.65-0.99] | 8.01 | 0.71 | 0.82 |
| | | WBC | 0.58 | [0.28-0.87] | 21.20 | 0.57 | 0.66 |
| | | CRP | 0.51 | [0.25-0.77] | 286 | 0.57 | 0.53 |
| | | Creatinine | 0.70 | [0.45-0.95] | 150 | 0.71 | 0.76 |
| | no SS vs SS | G-CSF | 0.76 | [0.64-0.88] | 334.3 | 0.55 | 0.97 |
| | | S100A8 | 0.72 | [0.58-0.85] | 289.47 | 0.57 | 0.89 |
| | | IL-6 | 0.82 | [0.71-0.93] | 467.5 | 0.62 | 0.97 |
| | | WBC | 0.51 | [0.36-0.67] | 20.8 | 0.69 | 0.47 |
| Sepsis cohort | no SS vs SS | CRP | 0.64 | [0.5-0.78] | 265.5 | 0.62 | 0.63 |
| | | Creatinine | 0.69 | [0.56-0.83] | 97.5 | 0.76 | 0.67 |
| | | G-CSF | 0.83 | [0.65-1] | 23.66 | 0.73 | 0.83 |
| | | S100A8 | 0.76 | [0.57-0.96] | 112.96 | 0.73 | 0.69 |
| | no SS vs SS | IL-6 | 0.85 | [0.68-1] | 308.81 | 0.8 | 0.77 |
| | | WBC | 0.47 | [0.21-0.74] | 10.65 | 0.64 | 0.62 |
| | | CRP | 0.44 | [0.19-0.69] | 105 | 0.64 | 0.54 |
| | | Creatinine | 0.93 | [0.79-1] | 117.5 | 1 | 0.92 |

NSTI: Necrotizing soft tissue infection, type I: Polymicrobial culture, type II: monomicrobial culture, GAS: Group A *Streptococcus*, SS: Septic shock, CI: Confidence interval, WBC: White blood cells, CRP: C-reactive protein

Table S8. Uni- and multivariate logistic regression analyses performed in the validation cohort.

| | Samples | Analyte | Univariate | | | Multivariate* | | |
|--|---|----------------|------------|-------------|---------|---------------|-------------|---------|
| | | | OR | [95% CI] | p-value | OR | [95% CI] | p-value |
| NSTI Sepsis vs NSTI | Thrombomodulin WBC CRP Creatinine | Thrombomodulin | 2.79 | [1.63-5.18] | <0.001 | 3.01 | [1.42-7.52] | 0.003 |
| | | WBC | 2.29 | [1.41-4.02] | <0.001 | 2.62 | [1.34-5.93] | 0.00 |
| | | CRP | 2.31 | [1.48-3.85] | <0.001 | 1.85 | [1.03-3.5] | 0.039 |
| | | Creatinine | 0.95 | [0.54-1.71] | 0.86 | 0.58 | [0.23-1.33] | 0.20 |
| NSTI cohort Type I vs Type II | CXCL-10 MMP-9 IL-10 Fas-Ligand IL-2 WBC CRP Creatinine | CXCL-10 | 1.37 | [1.15-1.7] | <0.001 | 1.39 | [1.16-1.76] | <0.001 |
| | | MMP-9 | 0.60 | [0.36-0.95] | 0.03 | 0.49 | [0.27-0.82] | 0.01 |
| | | IL-10 | 1.23 | [1-1.54] | 0.045 | 1.31 | [1.04-1.71] | 0.023 |
| | | Fas-Ligand | 1.15 | [0.69-1.94] | 0.59 | 1.06 | [0.63-1.8] | 0.84 |
| Type NSTI cohort Type I vs GAS | CXCL-10 MMP-9 IL-10 Fas-Ligand IL-2 WBC CRP Creatinine | IL-2 | 1.28 | [0.78-2.22] | 0.321 | 1.22 | [0.72-2.17] | 0.45 |
| | | WBC | 0.66 | [0.35-1.2] | 0.17 | 0.63 | [0.32-1.15] | 0.14 |
| | | CRP | 1.06 | [0.6-1.92] | 0.849 | 1.05 | [0.59-1.91] | 0.87 |
| | | Creatinine | 1.65 | [0.9-3.19] | 0.11 | 1.64 | [0.86-3.32] | 0.14 |
| Septic Shock no SS vs SS | G-CSF S100A8 IL-6 WBC CRP Creatinine | CXCL-10 | 2.12 | [1.43-21.4] | <0.001 | 1.68 | [1.3-5.23] | <0.001 |
| | | MMP-9 | 0.74 | [0.35-1.49] | 0.39 | 0.69 | [0.31-1.4] | 0.31 |
| | | IL-10 | 1.52 | [1.14-2.25] | 0.003 | 1.92 | [1.23-3.53] | 0.003 |
| | | Fas-Ligand | 2.16 | [0.97-6.26] | 0.06 | 2.64 | [1.03-9.94] | 0.04 |
| Septic Shock Sepsis cohort no SS vs SS | G-CSF S100A8 IL-6 WBC CRP Creatinine | IL-2 | 1.78 | [1.03-3.33] | 0.041 | 1.96 | [0.96-4.73] | 0.064 |
| | | WBC | 0.89 | [0.39-2.58] | 0.80 | 0.93 | [0.42-2.44] | 0.87 |
| | | CRP | 0.96 | [0.45-2.38] | 0.928 | 0.88 | [0.39-2.16] | 0.768 |
| | | Creatinine | 2.25 | [0.93-6] | 0.072 | 2 | [0.73-6.48] | 0.181 |

NSTI: Necrotizing soft tissue infection, Type I: Polymicrobial culture, Type II: monomicrobial culture, GAS: Group A *Streptococcus*, SS: Septic shock, CI: Confidence interval, WBC: White blood cells, CRP: C-reactive protein.

*Logistic regression including age, sex and SOFA




Figure S4. Association networks of measured analytes in the surgical control, Non-NSTI control and NSTI discovery cohorts. The non- NSTI patients are suspected NSTI cases but that had no necrotic tissue upon surgical exploration. The strength of the partial correlation between analytes is shown by the color and the weight of the connection.




Figure S5. Association networks of measured analytes in samples of NSTI patients with or without septic shock. The networks are based on the discovery cohort measurements. The colors of the analytes indicate the category of the analytes. The strength of the partial correlation between analytes is shown by the color and the weight of the connection.

Table S9. Connectivity values for each measured analyte in the discovery cohort. Samples were aggregated by type. The differential connectivity and q-values were calculated for the comparison of septic shock development within each NSTI type. (*Continues in the next page*)

| Analyte | Type I | | | | Type II | | | | |
|---------|------------------------|-------------|---------------------------|-------------|--------------|-------------|---------------------------|-------------|--------------|
| | Connectivity | | Differential connectivity | q-value | Connectivity | | Differential connectivity | q-value | |
| | no SS | SS | | | no SS | SS | | | |
| I | CCL2/MCP-1 | 0.74 | 0.49 | 0.26 | 0.002 | 0.50 | 0.77 | 0.27 | 0.001 |
| | CCL4/MIP-1 β | 0.21 | 0.34 | 0.13 | 0.003 | 0.28 | 0.55 | 0.26 | 0.001 |
| | CCL5/RANTES | 0.49 | 0.33 | 0.16 | 0.010 | 0.37 | 0.77 | 0.39 | 0.001 |
| | CXCL-8/IL-8 | 0.70 | 0.30 | 0.41 | 0.002 | 0.48 | 0.54 | 0.06 | 0.041 |
| | CXCL10/IP-10 | 0.26 | 0.47 | 0.21 | 0.002 | 0.32 | 0.87 | 0.55 | 0.001 |
| II | IL-1 α | 0.81 | 0.17 | 0.64 | 0.002 | 0.69 | 1.07 | 0.38 | 0.001 |
| | IL-1 β | 0.70 | 0.29 | 0.40 | 0.002 | 0.46 | 0.51 | 0.05 | 0.097 |
| | IL-2 | 0.62 | 0.66 | 0.03 | 0.313 | 0.50 | 0.87 | 0.37 | 0.001 |
| | IL-4 | 0.90 | 0.29 | 0.61 | 0.002 | 0.61 | 0.63 | 0.02 | 0.505 |
| | IL-6 | 0.67 | 0.27 | 0.39 | 0.002 | 0.31 | 0.68 | 0.36 | 0.001 |
| | IL-10 | 0.00 | 0.00 | 0.00 | 0.833 | 0.37 | 0.11 | 0.26 | 0.001 |
| | IL-12p70 | 0.81 | 0.98 | 0.17 | 0.003 | 0.59 | 0.68 | 0.08 | 0.034 |
| | IL-13 | 0.49 | 0.75 | 0.25 | 0.002 | 0.59 | 0.86 | 0.27 | 0.001 |
| | IL-17A | 0.09 | 0.73 | 0.64 | 0.002 | 0.30 | 0.59 | 0.28 | 0.001 |
| | IL-18 | 0.52 | 0.13 | 0.39 | 0.002 | 0.30 | 0.90 | 0.60 | 0.001 |
| III | IL-22 | 0.69 | 0.72 | 0.02 | 0.454 | 0.64 | 0.85 | 0.21 | 0.001 |
| | IL-36 β /IL-1F8 | 0.96 | 0.85 | 0.12 | 0.025 | 0.42 | 0.65 | 0.23 | 0.001 |
| | E-Selectin | 0.74 | 0.88 | 0.14 | 0.018 | 0.55 | 0.87 | 0.32 | 0.001 |
| | ICAM-1 | 0.27 | 0.55 | 0.28 | 0.002 | 0.53 | 0.84 | 0.31 | 0.001 |
| | VCAM-1 | 0.84 | 0.36 | 0.48 | 0.002 | 0.29 | 0.29 | 0.00 | 0.767 |
| IV | MMP-1 | 0.54 | 0.37 | 0.17 | 0.003 | 0.18 | 0.89 | 0.71 | 0.001 |
| | MMP-8 | 0.55 | 0.37 | 0.18 | 0.002 | 0.40 | 0.69 | 0.28 | 0.001 |
| | MMP-9 | 0.20 | 0.58 | 0.38 | 0.002 | 0.46 | 0.14 | 0.31 | 0.001 |
| V | C5/C5a | 0.47 | 0.13 | 0.34 | 0.002 | 0.31 | 0.64 | 0.33 | 0.001 |
| | Collagen-IV α 1 | 0.51 | 0.64 | 0.13 | 0.010 | 0.21 | 0.59 | 0.38 | 0.001 |
| | Fas-Ligand | 0.21 | 0.44 | 0.23 | 0.002 | 0.24 | 0.38 | 0.14 | 0.011 |
| | Galectin-3 | 0.40 | 0.28 | 0.13 | 0.009 | 0.34 | 1.19 | 0.84 | 0.001 |
| | G-CSF | 0.68 | 0.20 | 0.48 | 0.002 | 0.41 | 1.15 | 0.74 | 0.001 |
| | I-alpha-1/COL1A1 | 0.40 | 0.44 | 0.04 | 0.205 | 0.28 | 1.03 | 0.74 | 0.001 |
| | MPO | 0.53 | 0.42 | 0.10 | 0.049 | 0.83 | 0.71 | 0.12 | 0.006 |
| | Pentraxin-3 | 0.45 | 0.48 | 0.03 | 0.293 | 0.27 | 0.93 | 0.66 | 0.001 |
| | Resistin | 0.97 | 1.01 | 0.04 | 0.313 | 0.26 | 0.89 | 0.63 | 0.001 |
| | S100A8 | 0.29 | 0.33 | 0.04 | 0.205 | 0.59 | 0.84 | 0.25 | 0.001 |
| | S100A9 | 0.59 | 0.42 | 0.17 | 0.002 | 0.53 | 0.49 | 0.05 | 0.075 |

| | | | | | | | | |
|----------------|------|------|------|-------|-------------|-------------|-------------|--------------|
| Thrombomodulin | 0.42 | 0.46 | 0.04 | 0.313 | 0.49 | 1.46 | 0.98 | 0.001 |
| TNF α | 0.82 | 0.40 | 0.42 | 0.002 | 0.57 | 0.74 | 0.18 | 0.001 |

Categories: I-Chemokines, II-Interleukins, III-Soluble adhesion molecules, IV- Matrix metalloproteases, and V-Others. Type I: Polymicrobial culture, SS: Septic shock.

Table S10. Summary of the raw data for the discovery cohort. The numbers of values below (OOR <) or over (OOR >) the range are displayed in the first set of columns. The last two sets of columns display the statistical summary of the data before and after imputation. (*Continues in the next page*)

| Analyte | OOR data | | | | | | Raw | | | Imputed | | | |
|---------|------------------------|------------|------------|------------|------------|------------|-----------------|---------------|---------|-----------------|---------------|---------|---------|
| | OOR > # | OOR < % | OOR < # | OOR < % | Total # | Total % | Median pg/ml | Mean pg/ml | SD | Median pg/ml | Mean pg/ml | SD | |
| I | CCL2/MCP-1 | 0 | 0% | 0 | 0% | 0 | 0% | 438 | 1840 | 5570 | 438 | 1840 | 5570 |
| | CCL4/MIP-1 β | 0 | 0% | 0 | 0% | 0 | 0% | 768 | 811 | 453 | 768 | 811 | 453 |
| | CCL5/RANTES | 10 | 3% | 0 | 0% | 10 | 3% | 6523 | 10268 | 10954 | 6753 | 11893 | 13979 |
| | CXCL-8/IL-8 | 5 | 2% | 1 | 0% | 6 | 2% | 30 | 321 | 1408 | 31 | 563 | 2358 |
| | CXCL10/IP-10 | 40 | 13% | 0 | 0% | 40 | 13% | 151 | 1730 | 5981 | 197 | 51320 | 128964 |
| II | IL-1 α | 0 | 0% | 0 | 0% | 0 | 0% | 44 | 58 | 228 | 44 | 58 | 228 |
| | IL-1 β | 0 | 0% | 49 | 16% | 49 | 16% | 16 | 31 | 62 | 13 | 26 | 58 |
| | IL-2 | 0 | 0% | 18 | 6% | 18 | 6% | 473 | 676 | 577 | 426 | 637 | 581 |
| | IL-4 | 0 | 0% | 1 | 0% | 1 | 0% | 180 | 187 | 71 | 180 | 186 | 72 |
| | IL-6 | 20 | 6% | 0 | 0% | 20 | 6% | 225 | 2056 | 7647 | 263 | 6372 | 18022 |
| | IL-10 | 1 | 0% | 24 | 8% | 25 | 8% | 31 | 151 | 672 | 25 | 168 | 816 |
| | IL-12p70 | 0 | 0% | 44 | 14% | 44 | 14% | 141 | 168 | 179 | 128 | 144 | 176 |
| | IL-13 | 0 | 0% | 0 | 0% | 0 | 0% | 1159 | 1220 | 653 | 1159 | 1220 | 653 |
| | IL-17A | 0 | 0% | 36 | 12% | 36 | 12% | 17 | 48 | 144 | 15 | 42 | 136 |
| | IL-18 | 2 | 1% | 0 | 0% | 2 | 1% | 416 | 699 | 1092 | 423 | 760 | 1327 |
| III | IL-22 | 0 | 0% | 5 | 2% | 5 | 2% | 94 | 104 | 133 | 93 | 102 | 132 |
| | IL-36 β /IL-1F8 | 0 | 0% | 0 | 0% | 0 | 0% | 14 | 14 | 6 | 14 | 14 | 6 |
| | E-Selectin | 1 | 0% | 0 | 0% | 1 | 0% | 88779 | 111397 | 104435 | 89170 | 114977 | 121780 |
| | ICAM-1 | 0 | 0% | 0 | 0% | 0 | 0% | 545284 | 614431 | 301954 | 545284 | 614431 | 301954 |
| | VCAM-1 | 0 | 0% | 0 | 0% | 0 | 0% | 3300000 | 3822748 | 2774715 | 3300000 | 3822748 | 2774715 |
| IV | MMP-1 | 3 | 1% | 0 | 0% | 3 | 1% | 1508 | 2654 | 4021 | 1517 | 3029 | 5515 |
| | MMP-8 | 0 | 0% | 0 | 0% | 0 | 0% | 21420 | 38068 | 55423 | 21420 | 38068 | 55423 |
| | MMP-9 | 19 | 6% | 0 | 0% | 19 | 6% | 10661 | 22758 | 38480 | 12209 | 46289 | 99356 |
| V | C5/C5a | 0 | 0% | 0 | 0% | 0 | 0% | 20311 | 27081 | 21269 | 20311 | 27081 | 21269 |
| | Collagen-IV α 1 | 0 | 0% | 0 | 0% | 0 | 0% | 1744 | 2317 | 2058 | 1744 | 2317 | 2058 |
| | Fas-Ligand | 0 | 0% | 0 | 0% | 0 | 0% | 25 | 34 | 31 | 25 | 34 | 31 |
| | Galectin-3 | 0 | 0% | 0 | 0% | 0 | 0% | 3096 | 3373 | 1366 | 3096 | 3373 | 1366 |
| | G-CSF | 16 | 5% | 0 | 0% | 16 | 5% | 422 | 7263 | 33274 | 454 | 28764 | 97703 |
| | I-alpha-1/COL1A1 | 29 | 9% | 0 | 0% | 29 | 9% | 7552 | 8900 | 6515 | 7926 | 22519 | 42846 |
| | MPO | 1 | 0% | 0 | 0% | 1 | 0% | 34596 | 39053 | 22726 | 34762 | 39424 | 23605 |
| | Pentraxin-3 | 0 | 0% | 2 | 1% | 2 | 1% | 7007 | 13606 | 19296 | 6959 | 13518 | 19264 |
| | Resistin | 0 | 0% | 0 | 0% | 0 | 0% | 45965 | 44708 | 23887 | 45965 | 44708 | 23887 |
| | S100A8 | 0 | 0% | 0 | 0% | 0 | 0% | 633 | 1083 | 2339 | 633 | 1083 | 2339 |
| | S100A9 | 7 | 2% | 5 | 2% | 12 | 4% | 2197 | 5455 | 14986 | 2213 | 9707 | 32129 |

| | | | | | | | | | | | | |
|----------------|---|----|---|----|---|----|-------|-------|------|-------|-------|------|
| Thrombomodulin | 0 | 0% | 0 | 0% | 0 | 0% | 10228 | 11332 | 5970 | 10228 | 11332 | 5970 |
| TNF α | 0 | 0% | 0 | 0% | 0 | 0% | 23 | 43 | 150 | 23 | 43 | 150 |

Categories: I-Chemokines, II-Interleukins, III-Soluble adhesion molecules, IV- Matrix metalloproteases, and V-Others. OOR: Out of range, SD: Standard deviation